Analysts

Goldman Sachs Reports Hedge Funds Experience Worst Underperformance Against S&P 500 in Over 20 Years

08/20/2026, 10:36 PM research finance semiconductors

Hedge funds experienced their worst monthly underperformance against the S&P 500 in over two decades during July, largely due to a significant unwinding of AI investments, according to Goldman Sachs. This shift indicates a potential change in hedge fund strategies as they begin to diversify away from AI-focused positions.

JPMorgan’s James Sullivan Warns U.S. Treasury Market Intervention May Shift Debt Issues Rather Than Resolve Them

08/20/2026, 08:36 PM research finance ai JPMorgan Chase

JPMorgan warns that the U.S. Treasury's strategy of increasing debt buybacks may only provide temporary relief while failing to address the underlying debt burden, which could complicate market dynamics and investor choices.

Treasury Secretary Scott Bessent Faces Challenges in Addressing Liquidity Issues in the Government Debt Market

08/20/2026, 01:36 PM economy research

Treasury Secretary Scott Bessent's recent attempts to stabilize the government debt market through accelerated buybacks have faced skepticism, raising concerns about their effectiveness and the overall credibility of Treasury communications. Investors are closely watching how these strategies will impact yields and market confidence moving forward.

Analysts Citi downgraded TJX Companies (TJX) to neutral with a price target lowered to $154 due to disappointing Marmaxx performance

08/20/2026, 11:36 AM business rating_drop Analysts: analysts, Citi retail TJX

TJX Companies' shares have declined approximately 6% following a disappointing performance in its Marmaxx segment, which fell short of sales expectations. This situation may present a buying opportunity for investors as the company anticipates improvements in the coming months.

Analysts express caution on Meta Platforms (META) despite bullish ratings and low price-earnings ratio

08/20/2026, 10:37 AM investing review Analysts: analysts internet Meta Platforms

Meta Platforms' stock appears undervalued according to fundamental analysts, but technical indicators suggest a potential downturn, raising concerns for long-term investors.

Analysts Fundstrat Global Advisors highlight top stock picks for fall, including JPMorgan Chase (JPM) and Lumentum Holdings (LITE)

08/20/2026, 09:36 AM review Analysts: analysts, JPMorgan finance ai JPMorgan Chase Lumentum Holdings

Tom Lee of Fundstrat Global Advisors remains optimistic about the stock market as the fourth quarter approaches, highlighting specific stocks to buy and avoid based on a proprietary selection model.

Analysts Ritholtz Wealth Management spotlight SharkNinja, Inc. (SN) as a top stock with 337% return since IPO

08/20/2026, 08:37 AM investing review Analysts: analysts, Ritholtz consumer SharkNinja, Inc.

SharkNinja, Inc. (SN) has emerged as a standout stock, achieving a remarkable 337% return since its IPO in 2023, driven by strong fundamentals and significant growth in its product categories. Investors are advised to monitor the stock for potential entry points after its recent surge.

Analysts JPMorgan initiated coverage of UMB Financial (UMBF) with an overweight rating and a price target of $180 by December 2027, anticipating a 578% increase

08/20/2026, 07:36 AM investing rating_growth Analysts: analysts, JPMorgan finance UMB Financial (UMBF) JPMorgan Chase

JPMorgan has initiated coverage of UMB Financial with an overweight rating, projecting a significant share price increase due to the bank's expansion into diversified financial services.

Analysts Wells Fargo recommend buying Progyny (PGNY) shares with a target price of $37, indicating 45% upside

08/20/2026, 06:36 AM investing recommendation Analysts: analysts, Wells Fargo Progyny

Wells Fargo's initiation of coverage on Progyny with an overweight rating and a $37 price target indicates strong potential for growth in the fertility benefits management sector, suggesting a 45% upside for investors.

Analysts Morgan Stanley upgraded Merck & Co. (MRK) to Overweight and raised target price to $179, citing strong cancer drug pipeline

08/20/2026, 05:37 AM investing rating_growth Analysts: analysts, Morgan Stanley healthcare Merck

Morgan Stanley has upgraded Merck's stock to overweight, citing confidence in its drug pipeline to sustain growth despite the impending expiration of the Keytruda patent in 2028. The firm raised its price target for Merck shares to $179, indicating a potential 17% upside.